Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose escalation study of GSK1399686 in mild to moderately active ulcerative colitis
2009-011608-51Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK1399686 in autoimmune colitis (3 arms), sponsored by GSK. Primary endpoint: Primary - safety and tolerability. Started Jun 2009; status: completed.
02
Drugs
GSK1399686
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2009-011608-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011608-51.